Filing Analysis
Regulation FD Disclosure
Filed Mar 31, 2026
LOW
Turn Therapeutics Inc. announced its financial and operating results for the fiscal year ended December 31, 2025, via a press release furnished with the filing.
Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The press release was issued and the 8-K filed on March 31, 2026.
- The company is classified as an emerging growth company.
Material Agreement
Filed Mar 24, 2026
HIGH
Turn Therapeutics entered into a $25 million loan and security agreement with Avenue Venture Opportunities Fund II, L.P., securing an initial $7 million tranche. The debt is high-cost, secured by all company assets including intellectual property, and includes significant dilutive components such as an upfront equity grant and a discounted conversion option.
Red Flags
- High interest rate (minimum 12.25%) relative to traditional corporate debt.
- Significant dilution risk from the $1.2M upfront equity grant and the 20% discount on the debt conversion option.
- All intellectual property is pledged as collateral, creating high risk in the event of default.
- Future funding tranches are conditional on milestones, which may create liquidity pressure if clinical trials face delays.
Key Facts
- Total loan facility of up to $25.0 million across three tranches, with $7.0 million funded immediately.
- Interest rate is the greater of (Prime + 5.50%) or 12.25% per annum.
- The loan is secured by a lien on all company assets, including intellectual property.
- Issued $1.2 million in common stock to the lender as an upfront equity grant.
- Lender has a conversion option for up to $3.0 million of principal at a 20% discount to the market price (80% of closing price).
- Tranches 2 ($8M) and 3 ($10M) are contingent upon clinical and financing milestones.
- Maturity date is set for October 1, 2029, with a final payment fee of 3.75% of the total funded amount.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.